Tumor Ablation Market-Forecast till 2030

As per the MRFR analysis, the global tumor ablation market is estimated to witness a notable CAGR of 11.81% during the forecast period to surpass USD 2,459.74 million by the end of 2030. The major market participants in the market are proactively dealing with R&D for improving and propelling methods for tumor ablation. Moreover, there are likewise a few dangers related to the radiofrequency removal method, for example, hyperesthesia, shallow skin contaminations over the infusion site, heat harm to structures contiguous to the objective nerve, hypersensitive response to the sedative used to numb the skin, and that's only the tip of the iceberg.

The developing pervasiveness of disease is expanding the interest for compelling treatment. Unreasonable smoking and utilization of liquor and tobacco are the significant variables answerable for the rising predominance of malignant growth across the world. Expanding commonness of disease across the globe goes about as a significant driver in the worldwide tumor ablation market from 2021-to to 2030. Nonetheless, incidental effects and entanglement related to tumor ablation thwart the development of the worldwide tumor ablation market during the gauge time frame. Rising R&D exercises in tumor ablation are supposed to set out freedom in the worldwide tumor ablation market.

Market Segmentation

The market segmentation of the global tumor ablation market is carried out in terms of technology, treatment, application, and end-user.

The application segment of the global tumor ablation market is categorized into liver cancer, lung cancer, kidney cancer, and others. The treatment type divides the market based on surgical ablation, and percutaneous ablation laparoscopic ablation. Europe is the second-biggest market for growth ablation because of the development of normalized strategies and instruments for cancer ablation therapy, developing interest in medical procedure radiotherapy and chemotherapy for early recognized growths, and expanding instances of different cancer among the mid-matured and geriatric populace, and rising utilization of undesirable and cancer-causing items.

Regional Analysis

Geographically, the global tumor ablation market spans North America, Europe, Asia-Pacific, Rest of the World.

North America contributed the largest market of 40.29% in 2020 and is anticipated to lead the market during the review period. The regional market is driven by the advances in percutaneous ablation, developing interest in radiofrequency ablation for hepatocellular carcinoma, expanding geriatric populace, and development of cancer-related issues among the populace matured 65 years or more.

Europe is the second-biggest market for growth ablation because of the development of normalized strategies and instruments for cancer ablation therapy, developing interest in medical procedure radiotherapy and chemotherapy for early recognized growths, and expanding instances of different cancer among the mid-matured and geriatric populace, and rising utilization of undesirable and cancer-causing items. Asia-Pacific is supposed to fill essentially in the growth ablation market inferable from the rising utilization of cancer-causing items, for example, liquor and betel nut, restricted admission of leafy foods, a disclosure to indoor and open-air contamination, and ascend in openness to compound poisons across the region.

Key Competitors

The key players operating in the global tumor ablation include SonaCare Medical, LLC (US), Medtronic plc (Ireland), EDAP TMS (France), Angio Dynamics (US), HealthTronics, Inc (US), Johnson & Johnson (US), Boston Scientific Corporation (US), Misonix Inc (US), HistoSonics, Inc (US), Biotronik (Germany).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Product Code: MRFR/HC/5673-CR

1 EXECUTIVE SUMMARY 15

1.1.1 MARKET SYNOPSIS 15

2 MARKET INTRODUCTION 16

2.1 SCOPE OF THE STUDY 16
2.2 RESEARCH OBJECTIVE 16
2.3 LIST OF ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 18

3.1 DATA MINING 18
3.2 SECONDARY RESEARCH 19
3.3 PRIMARY RESEARCH 20
- 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 20
- 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS 21
3.4 FORECASTING TECHNIQUES 21
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
- 3.5.1 BOTTOM-UP APPROACH 23
- 3.5.2 TOP-DOWN APPROACH 24
3.6 DATA TRIANGULATION 24
3.7 VALIDATION 24

4 MARKET DYNAMICS 26

4.1 OVERVIEW 26
4.2 DRIVERS 27
- 4.2.1 INCREASING PREVALENCE OF CANCER ACROSS THE GLOBE 27
- 4.2.2 RISING DEMAND FOR MINIMALLY INVASIVE TUMOR ABLATION TECHNIQUES 27
- 4.2.3 GROWING NUMBER OF PUBLIC-PRIVATE INITIATIVES AND FUNDING TO SUPPORT ONGOING RESEARCH ACTIVITIES RELATED TO TUMOR ABLATION 27
4.3 RESTRAINTS 28
- 4.3.1 SIDE-EFFECTS AND COMPLICATIONS ASSOCIATED WITH TUMOR ABLATION 28
- 4.3.2 DELAY IN APPROVAL AND UNFAVORABLE REGULATORY POLICY AND REIMBURSEMENT SCENARIO 28
4.4 OPPORTUNITY 29
- 4.4.1 RISING R&D ACTIVITIES 29

5 MARKET FACTOR ANALYSIS 30

5.1 VALUE CHAIN ANALYSIS 30
- 5.1.1 R&D 31
- 5.1.2 MANUFACTURING 31
- 5.1.3 DISTRIBUTION & SALES 31
- 5.1.4 POST-SALES MONITORING 31
5.2 PORTER'S FIVE FORCES ANALYSIS 32
- 5.2.1 THREAT OF NEW ENTRANTS 33
- 5.2.2 BARGAINING POWER OF SUPPLIERS 33
- 5.2.3 BARGAINING POWER OF BUYERS 33
- 5.2.4 THREAT OF SUBSTITUTES 33
- 5.2.5 INTENSITY OF RIVALRY 33
5.3 COVID-19 IMPACT ANALYSIS 34
- 5.3.1 IMPACT ON AVAILABILITY OF SURGICAL FACILITIES 34
- 5.3.2 IMPACT ON KEY PLAYERS 34
- 5.3.3 IMPACT ON CLINICAL TRIALS 35
- 5.3.4 IMPACT ON SUPPLY CHAIN 35

6 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY 36

6.1 OVERVIEW 36
6.2 RADIOFREQUENCY 37
6.3 MICROWAVE 37
6.4 IRREVERSIBLE ELECTROPORATION 38
6.5 CRYOABLATION 39
6.6 OTHERS 40

7 GLOBAL TUMOR ABLATION MARKET, BY TREATMENT 41

7.1 OVERVIEW 41
7.2 SURGICAL ABLATION 42
7.3 PERCUTANEOUS ABLATION 42
7.4 LAPAROSCOPIC ABLATION 43

8 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION 44

8.1 OVERVIEW 44
8.2 LUNG CANCER 45
8.3 KIDNEY CANCER 45
8.4 LIVER CANCER 46
8.5 OTHERS 47

9 GLOBAL TUMOR ABLATION MARKET, BY END USER 48

9.1 OVERVIEW 48
9.2 HOSPITAL AND CLINICS 49
9.3 SPECIALITY CENTERS 50
9.4 OTHERS 50

10 GLOBAL TUMOR ABLATION MARKET, BY REGION 51

10.1 OVERVIEW 51
10.2 NORTH AMERICA 52
- 10.2.1 US 55
- 10.2.2 CANADA 56
10.3 EUROPE 58
- 10.3.1 GERMANY 61
- 10.3.2 FRANCE 62
- 10.3.3 UK 63
- 10.3.4 ITALY 65
- 10.3.5 SPAIN 66
- 10.3.6 REST OF EUROPE 67
10.4 ASIA PACIFIC 69
- 10.4.1 CHINA 71
- 10.4.2 INDIA 72
- 10.4.3 JAPAN 74
- 10.4.4 SOUTH KOREA 75
- 10.4.5 AUSTRALIA 76
- 10.4.6 REST OF ASIA PACIFIC 78
10.5 REST OF THE WORLD 80
- 10.5.1 MIDDLE EAST 82
- 10.5.2 AFRICA 84
- 10.5.3 LATIN AMERICA 85

11 COMPETITIVE LANDSCAPE 87

11.1 OVERVIEW 87
11.2 COMPETITIVE BENCHMARKING 88
11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL TUMOR ABLATION MARKET 89
11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL TUMOR ABLATION MARKET 90
11.5 KEY DEVELOPMENT ANALYSIS 90
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 91
- 11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 91
- 11.6.2 MERGER &ACQUISITION 91
11.7 FINANCIAL MATRIX 92
- 11.7.1 SALES (USD MILLION), 2020 92
- 11.7.2 R&D EXPENDITURE (USD MILLION), 2020 92

12 DRG COST OF CURATIVE TREATMENT 93

12.1 DIAGNOSIS-RELATED GROUP (DRG) 93
12.2 BIOPSY PROCEDURE REIMBURSEMENT 93
12.3 ABLATION PROCEDURE REIMBURSMENT 93
- 12.3.1 LIVER ABLATION PROCEDURE REIMBURSMENT 94
- 12.3.2 KIDNEY ABLATION PROCEDURE REIMBURSMENT 94
- 12.3.3 LUNG ABLATION PROCEDURE REIMBURSMENT 95
12.4 IMAGING PROCEDURE REIMBURSMENT 95
12.5 TOTAL CURATIVE TREATMENT COSTS 96

13 COMPANY PROFILES 97

13.1 SONACARE MEDICAL 97
- 13.1.1 COMPANY OVERVIEW 97
- 13.1.2 FINANCIAL OVERVIEW 97
- 13.1.3 PRODUCTS/SERVICES OFFERED 97
- 13.1.4 KEY DEVELOPMENTS 97
- 13.1.5 SWOT ANALYSIS 98
- 13.1.6 KEY STRATEGIES 98
13.2 MEDTRONIC PLC 99
- 13.2.1 COMPANY OVERVIEW 99
- 13.2.2 FINANCIAL OVERVIEW 99
- 13.2.3 PRODUCTS/SERVICES OFFERED 100
- 13.2.4 KEY DEVELOPMENTS 100
- 13.2.5 SWOT ANALYSIS 100
- 13.2.6 KEY STRATEGIES 101
13.3 EDAP TMS 102
- 13.3.1 COMPANY OVERVIEW 102
- 13.3.2 FINANCIAL OVERVIEW 102
- 13.3.3 PRODUCTS/SERVICES OFFERED 103
- 13.3.4 KEY DEVELOPMENTS 103
- 13.3.5 SWOT ANALYSIS 103
- 13.3.6 KEY STRATEGIES 103
13.4 ANGIODYNAMICS 104
- 13.4.1 COMPANY OVERVIEW 104
- 13.4.2 FINANCIAL OVERVIEW 104
- 13.4.3 PRODUCTS/SERVICES OFFERED 105
- 13.4.4 KEY DEVELOPMENTS 105
- 13.4.5 SWOT ANALYSIS 105
- 13.4.6 KEY STRATEGIES 105
13.5 HEALTHTRONICS, INC. 106
- 13.5.1 COMPANY OVERVIEW 106
- 13.5.2 FINANCIAL OVERVIEW 106
- 13.5.3 PRODUCTS/SERVICES OFFERED 106
- 13.5.4 KEY DEVELOPMENTS 106
- 13.5.5 SWOT ANALYSIS 107
- 13.5.6 KEY STRATEGIES 107
13.6 JOHNSON & JOHNSON 108
- 13.6.1 COMPANY OVERVIEW 108
- 13.6.2 FINANCIAL OVERVIEW 108
- 13.6.3 PRODUCTS/SERVICES OFFERED 109
- 13.6.4 KEY DEVELOPMENTS 109
- 13.6.5 SWOT ANALYSIS 109
- 13.6.6 KEY STRATEGIES 109
13.7 BOSTON SCIENTIFIC CORPORATION 110
- 13.7.1 COMPANY OVERVIEW 110
- 13.7.2 FINANCIAL OVERVIEW 110
- 13.7.3 PRODUCTS/SERVICES OFFERED 111
- 13.7.4 KEY DEVELOPMENTS 111
- 13.7.5 SWOT ANALYSIS 111
- 13.7.6 KEY STRATEGIES 112
13.8 MISONIX, INC. 113
- 13.8.1 COMPANY OVERVIEW 113
- 13.8.2 FINANCIAL OVERVIEW 113
- 13.8.3 PRODUCTS/SERVICES OFFERED 114
- 13.8.4 KEY DEVELOPMENTS 114
- 13.8.5 SWOT ANALYSIS 114
- 13.8.6 KEY STRATEGIES 115
13.9 HISTOSONICS, INC. 116
- 13.9.1 COMPANY OVERVIEW 116
- 13.9.2 FINANCIAL OVERVIEW 116
- 13.9.3 PRODUCTS/SERVICES OFFERED 116
- 13.9.4 KEY DEVELOPMENTS 116
- 13.9.5 SWOT ANALYSIS 117
- 13.9.6 KEY STRATEGIES 117
13.10 BIOTRONIK 118
- 13.10.1 COMPANY OVERVIEW 118
- 13.10.2 FINANCIAL OVERVIEW 118
- 13.10.3 PRODUCTS/SERVICES OFFERED 118
- 13.10.4 KEY DEVELOPMENTS 118
- 13.10.5 SWOT ANALYSIS 119
- 13.10.6 KEY STRATEGIES 119

14 APPENDIX 120

14.1 REFERENCES 120
14.2 RELATED REPORTS 120